

Many patients don't reach target dose of atomoxetine

August 11 2016



(HealthDay)—A considerable proportion of patients receiving

atomoxetine (ATX), especially those receiving ATX monotherapy, do not reach the recommended dose of 80 mg/day ($ATX \geq 80$), according to a study published online July 31 in *CNS Neuroscience & Therapeutics*.

David B. Clemow, Ph.D., from Lilly USA in Indianapolis, and colleagues conducted a retrospective observational cohort study involving adults with attention-deficit/hyperactivity disorder (ADHD). In patients prescribed ATX monotherapy (mono; 36,076 patients) and ATX in combination with other ADHD medications (combo; 1,548 patients), the authors compared ATX length of therapy (LoT) among those who reached the recommended dose ($ATX \geq 80$) versus those who did not (ATX

Citation: Many patients don't reach target dose of atomoxetine (2016, August 11) retrieved 9 April 2024 from <https://medicalxpress.com/news/2016-08-patients-dont-dose-atomoxetine.html>

| |
|---|
| This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. |
|---|